A5038155158- Clostridium difficile and Clostridium perfringens research
- Gut microbiota and health
- Gastrointestinal motility and disorders
- Microscopic Colitis
- Nosocomial Infections in ICU
- Helicobacter pylori-related gastroenterology studies
- Health disparities and outcomes
- Global Maternal and Child Health
- Global Public Health Policies and Epidemiology
- Liver Disease and Transplantation
- Adolescent Sexual and Reproductive Health
- Trauma and Emergency Care Studies
- HIV/AIDS Research and Interventions
- Clinical Nutrition and Gastroenterology
- Climate Change and Health Impacts
- Liver Disease Diagnosis and Treatment
- Viral gastroenteritis research and epidemiology
- Health and Conflict Studies
- Mycobacterium research and diagnosis
- Global Health Care Issues
- Cystic Fibrosis Research Advances
- Injury Epidemiology and Prevention
- Antibiotics Pharmacokinetics and Efficacy
- Reproductive tract infections research
- Infectious Disease Case Reports and Treatments
OpenBiome
2015-2024
Wellcome Sanger Institute
2024
University of Cambridge
2023
Harvard University
2016-2022
Finch Therapeutics (United States)
2022
Youth Development
2020
Youth Development Labs
2020
Boston Children's Hospital
2016-2017
University College London
2012
University College London Hospitals NHS Foundation Trust
2012
Hepatic encephalopathy (HE) can cause major morbidity despite standard of care (SOC; rifaximin/lactulose). Fecal microbial transplant (FMT) enemas postantibiotics are safe, but the effect FMT without antibiotics using capsular route requires investigation. The aim this work was to determine safety, tolerability, and impact on mucosal/stool microbiota brain function in HE after a randomized, single‐blind, placebo‐controlled clinical trial Virginia. Patients with cirrhosis recurrent MELD...
Abstract Fecal microbiota transplantation (FMT) is recommended therapy for multiply recurrent Clostridioides difficile infection. We report adverse events in 7 patients who received FMT from a stool donor was colonized with Shiga toxin–producing Escherichia coli (STEC). No died of FMT-transmitted STEC. Improved screening can likely avoid future transmission.
Abstract Changes in the microbiota have been linked to persistent inflammation during treated HIV infection. In this pilot double-blind study, we study 30 HIV-infected subjects on antiretroviral therapy (ART) with a CD4/CD8 ratio < 1 randomized either weekly fecal capsules or placebo for 8 weeks. Stool donors were rationally selected based their signatures. We report that transplantation (FMT) is safe, not related severe adverse events, and attenuates HIV-associated dysbiosis. FMT elicits...
Fecal microbiota transplantation (FMT) is recommended for the prevention of recurrent Clostridioides difficile infection (CDI).1Kelly C.R. et al.Am J Gastroenterol. 2021; 116: 1124-1147Crossref PubMed Scopus (202) Google Scholar Randomized trials have reported promising efficacy and safety among patients treated with FMT following standard care (SOC) CDI antibiotics compared SOC alone. However, these are small, methodological limitations.2Moayyedi P. al.Med Aust. 2017; 207: 166-172Crossref...
Early clinical successes are driving enthusiasm for fecal microbiota transplantation (FMT), the transfer of healthy gut bacteria through whole stool, as emerging research is linking microbiome to many different diseases. However, preliminary trials have yielded mixed results and suggest that heterogeneity in donor stool may play a role patient response. Thus, fail because an ineffective was chosen rather than FMT not appropriate indication. Here, we describe conceptual framework guide...
Fecal microbiota transplantation (FMT) is a recommended therapy to prevent recurrent Clostridioides difficile infection (CDI).1,2 Stool banks have emerged enable safe widespread access by provid...
The gastrointestinal microbiome is intrinsically linked to the spread of antibiotic resistance. Antibiotic treatment puts patients at risk for colonization by opportunistic pathogens like vancomycin resistant Enterococcus and <em>Clostridioides difficile</em> destroying resistance provided commensal microbiota. Once colonized, host a much higher infection that pathogen. Furthermore, we know community differences are associated with disease states, but do not have good understanding how can...
Here we report evidence of transfer atypical enteropathogenic Escherichia coli (aEPEC) using fecal microbiota transplant (FMT) to a patient treated for recurrent Clostridium difficile infection (CDI). FMT is an effective treatment CDI.1Cammarota G. et al.Gut. 2019; 68: 2111-2121Crossref PubMed Scopus (233) Google Scholar Extensive screening ensures donors are devoid numerous medical and significant health measures including but not limited gastrointestinal symptoms infections.2Kassam Z. al.N...
Abstract Antimicrobial resistance (AMR) poses an immediate danger to global health. If unaddressed, the current upsurge in AMR threatens reverse achievements reducing infectious disease–associated mortality and morbidity associated with antimicrobial treatment. Consequently, there is urgent need for strategies prevent or slow progress of AMR. Vaccines potentially contribute both directly indirectly combating Modeling studies have indicated significant gains from vaccination burdens specific...
Abstract Early clinical successes are driving enthusiasm for fecal microbiota transplantation (FMT), the transfer of healthy gut bacteria through whole stool, as emerging research is linking microbiome to many different diseases. However, preliminary trials have yielded mixed results and suggest that heterogeneity in donor stool may play a role patient response. Thus, fail because an ineffective was chosen rather than FMT not appropriate indication. Here, we describe conceptual framework...